Provided by Tiger Trade Technology Pte. Ltd.

Passage Bio, Inc.

6.89
-0.2050-2.89%
Post-market: 6.890.00000.00%16:10 EDT
Volume:9.48K
Turnover:66.68K
Market Cap:22.10M
PE:-0.48
High:7.27
Open:7.02
Low:6.88
Close:7.10
52wk High:20.00
52wk Low:5.12
Shares:3.21M
Float Shares:2.87M
Volume Ratio:0.20
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.3500
EPS(LYR):-14.3500
ROE:-113.78%
ROA:-32.75%
PB:1.18
PE(LYR):-0.48

Loading ...

Top Premarket Gainers

MT Newswires Live
·
Mar 19

Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway

TIPRANKS
·
Mar 10

Passage Bio Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 05

Passage Bio (PASG) Gets a Buy from Chardan Capital

TIPRANKS
·
Mar 04

Passage Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 03

Passage Bio Q4 EPS $(4.09) Misses $(2.68) Estimate

Benzinga
·
Mar 03

Passage Bio's 2025 net loss narrows

Reuters
·
Mar 03

Passage Bio FY 2025 net loss totals USD 45.5 million -29.7%

Reuters
·
Mar 03

Passage Bio Inc: Expects Current Cash and Cash Equivalents to Fund Operations Through 1Q 2027

THOMSON REUTERS
·
Mar 03

Passage Bio Inc: Advancing Differentiated Preclinical Program for Huntington's With Clinical Candidate Selection Expected in 2H 2026

THOMSON REUTERS
·
Mar 03

Press Release: Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

Dow Jones
·
Mar 03

Passage Bio Inc expected to post a loss of $2.57 a share - Earnings Preview

Reuters
·
Feb 27

Passage Bio to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 19

Passage Bio Highlights PBFT02 Progress and Extended Cash Runway

TIPRANKS
·
Jan 12

Passage Bio Unveils Gene Therapy Advances for Neurodegenerative Diseases

Reuters
·
Jan 12

Passage Bio Inc - Expects Cash to Fund Operations Into Q1 2027 - SEC Filing

THOMSON REUTERS
·
Jan 12

Chardan Raises Price Target on Passage Bio to $21 From $6, Keeps Buy Rating

MT Newswires Live
·
Nov 12, 2025

Passage Bio Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 12, 2025

Passage Bio (PASG) Receives a Buy from Chardan Capital

TIPRANKS
·
Nov 12, 2025

Wedbush Adjusts Passage Bio Price Target to $32 From $40, Maintains Outperform Rating

MT Newswires Live
·
Nov 12, 2025